Harrow
Greg Anderson has over three decades of experience in the medical device and pharmaceutical industry. Greg has held various leadership positions, including Vice President of Sales at Harrow Health, Inc., where they were responsible for growing a $90 million compounding pharmaceutical business. Prior to that, they served as Vice President of Sales at Ocular Science, where they led the commercial growth of the pharmaceutical and regenerative science businesses. Greg has also held leadership roles at Restoration Robotics, Abbott, OptiMedica Corporation, IntraLase Corporation, WaveLight, Inc., Coherent Inc., and American V. Mueller - Baxter Travenol. Throughout their career, Greg has demonstrated a track record of driving sales growth, implementing effective sales strategies, and developing strong customer relationships in the ophthalmology and medical technology sectors.
Greg Anderson attended the University of Maryland from 1979 to 1982, where they obtained a Bachelor of Science degree in Marketing. Greg also attended the University of Maryland - Robert H. Smith School of Business during the same period and earned a BS degree in Marketing.
This person is not in any offices
Harrow
2 followers
Harrow (Nasdaq: HROW) is a leading U.S. eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic prescription therapies that are accessible and affordable. Harrow owns U.S. commercial rights to ten FDA-approved ophthalmic pharmaceutical products. Harrow also owns and operates ImprimisRx, the leading U.S. ophthalmic‑focused pharmaceutical compounding business, which also serves as a mail-order pharmacy licensed to ship prescription medications in all 50 states. Harrow has non-controlling equity positions in Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc., companies that began as subsidiaries of Harrow. Harrow also owns royalty rights in four late-stage drug candidates being developed by Surface and Melt.